Jazz Pharmaceuticals and GW Pharmaceuticals will build a new manufacturing facility in Kent Science Park, Sittingbourne. The facility will produce two cannabis-based drugs as well as new drugs. Production is scheduled to begin in 2024. The investment will be $100 million.